Physician profile
Shellie Marthini
NPI 1790313419
$2,334.41
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $537 · 2022: $373 · 2023: $390 · 2024: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $708.34 | 2021-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.82 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $192.10 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $189.41 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $157.17 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $139.08 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $121.76 | 2023-2024 | Gemtesa |
| Lilly USA, LLC | $95.89 | 2021-2022 | |
| Amgen INC. | $88.95 | 2024 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $88.70 | 2023-2024 | |
| Novo Nordisk INC | $68.04 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $50.72 | 2024 | |
| Xeris Pharmaceuticals, INC. | $42.64 | 2024 | Gvoke Hypopen |
| Astellas Pharma US INC | $38.66 | 2024 | Veozah |
| Mylan Specialty L.P. | $37.38 | 2023 | Yupelri |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $28.70 | 2023-2024 | Livalo, Zoryve |
| Daiichi Sankyo INC. | $27.60 | 2024 | Injectafer |
| Exact Sciences Corporation | $18.45 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shellie Marthini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.